
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion Inc. is demonstrating promising progress in its clinical pipeline, particularly with icovamenib, which achieved a significant 1.2% reduction in HbA1c in the severe insulin-deficient subgroup over 52 weeks, indicating strong potential for durable glycemic control in type 2 diabetes patients. The company has further enhanced its outlook with the advancement of BMF-650, an oral GLP-1 receptor agonist, which has shown effective dose-dependent weight reductions in preclinical studies, and its successful progression into Phase I trials. Additionally, Biomea Fusion's financial performance reflects improvement, as the company narrowed its net loss to $16.4 million for Q3 2025 from $32.8 million in the prior year, indicating effective cost management alongside strategic investment in its drug development pipeline.
Bears say
Biomea Fusion Inc. reported a significant decline in research and development expenses, decreasing from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, while general and administrative expenses also saw a reduction from $6.8 million to $4.2 million. The decrease in R&D spending may indicate challenges in advancing its product candidates and could impact the company’s long-term growth potential. Additionally, the adjustment in the price target from $16.00 to $12.00 reflects a negative outlook, suggesting a reassessment of the company’s financial health and strategic direction.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares